Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

A new generative AI model rapidly generates diverse antimicrobial peptide structures for screening against ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Can-Fite’s lead drug candidate, Piclidenoson ... who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out ...

GSK said this reflected progress in late stage drug development, including several ... They’ve been held back by concern over the pipeline and what is seen as few near-term catalysts, down ...